ADC Therapeutics SA (ADCT) Misses Q3 EPS by 30c

ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.65), $0.30 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $76.32 million versus the consensus estimate of $60.7 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand